Suggestions
Jeroen Bakker
Partner at Novo Holdings
Jeroen Bakker is a Partner at Novo Holdings, specifically in the Seed Investments department. He joined Novo Holdings in September 2018, initially as a Principal, and has since been promoted to Partner.12
Jeroen has an extensive background in biotech and venture capital:
Education and Early Career
- PhD in Immunology from the University of Amsterdam
- MSc in Biomedical Sciences from Leiden University, with a specialization in entrepreneurship
- BSc from the Technical University of Delft
- Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego
Professional Experience
Before joining Novo Holdings, Jeroen worked at:
- M Ventures (corporate venture capital arm of Merck) focusing on Seed and Series A investments
- Various operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera, and ISD Immunotech
Current Responsibilities
At Novo Holdings, Jeroen:
- Holds several board positions
- Led investments in companies such as Adcendo and Rappta Therapeutics
- Focuses on identifying, building, and investing in innovative life science startups, particularly in the Nordic region
Board Positions
Jeroen currently serves on the boards of:
- Adcendo
- BiOrigin
- Rappta Therapeutics
- Antag Therapeutics
He previously held board positions at ISD-Immunotech and served as Interim Chief Business Officer there.2
Additional Information
Jeroen has also been involved in academic and professional organizations:
- Chair of the Dutch Platform for Young Researchers in Nephrology
- Member of REBBLS, a Danish networking organization for young biotech entrepreneurs
His LinkedIn username is indeed jeroenbakker, as mentioned in the query.2
Highlights
I recently spoke to Lucie Ellis-Taitt, following my recognition as one of In Vivo’s Rising Leaders.
It was great to discuss with Lucie Novo Holdings’ Seed Investments strategy and my passion for company creation in the biotech space, as well as the importance of creating talented leaders and cohesive teams. You can read the article using the link in the comments below.
I am honoured to have been recognised as one of In Vivo's Rising Leaders for 2024 alongside many talented CEOs, investors and entrepreneurs – thank you In Vivo (Citeline) for the recognition! #InVivosRisingLeaders2024
The potential of the platform behind Commit Biologics is huge! Have look at the interview with CEO Krishna Polu at Endpoints News.
